|
|
Volumn 69, Issue 14, 2012, Pages 1178-
|
|
FDA approves pertuzumab for breast cancer
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DOCETAXEL;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
PERJETA;
PERTUZUMAB;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
ANAPHYLAXIS;
BIRTH DEFECT;
BREAST CANCER;
CANCER COMBINATION CHEMOTHERAPY;
DIARRHEA;
DRUG APPROVAL;
DRUG INDICATION;
DRUG LABELING;
FATIGUE;
FETUS DEATH;
FOOD AND DRUG ADMINISTRATION;
HAIR LOSS;
HUMAN;
HYPERSENSITIVITY REACTION;
METASTASIS;
NAUSEA;
NEUTROPENIA;
NOTE;
PERIPHERAL NEUROPATHY;
PRIORITY JOURNAL;
RASH;
RECOMMENDED DRUG DOSE;
SIDE EFFECT;
|
|
EID: 84863896481
PISSN: 10792082
EISSN: 15352900
Source Type: Journal
DOI: 10.2146/news120049 Document Type: Note |
|
Times cited : (7)
|
|
References (0)
|
